Atheromatosis

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 234 Experts worldwide ranked by ideXlab platform

Jose M Valdivielso - One of the best experts on this subject based on the ideXlab platform.

  • association of the rs495392 klotho polymorphism with Atheromatosis progression in patients with chronic kidney disease
    Nephrology Dialysis Transplantation, 2019
    Co-Authors: Jose M Valdivielso, Elvira Fernandez, Milica Bozic, Rajesh Kumar Galimudi, Marcelino Bermudezlopez, Juan F Navarrogonzalez, Angels Betriu
    Abstract:

    Background Prevalence of atherosclerotic cardiovascular disease and its rate of progression are higher in patients with chronic kidney disease (CKD) compared with the general population. Mineral metabolism parameters have been shown to be involved in the increased velocity of Atheromatosis progression. The aim of this study is to determine the role of 11 single-nucleotide polymorphisms (SNPs) of the Klotho gene on the rate of atherosclerosis progression in CKD. Methods This was a multicentre, prospective, observational study of 1439 CKD patients from the NEFRONA cohort. Carotid and femoral ultrasounds were performed at baseline and after 24 months in 10 arterial territories. Progression of Atheromatosis was defined as an increase in the number of territories with plaque. Genotyping of 11 SNPs of the Klotho gene was performed and its association with Atheromatosis progression was determined by multivariate logistic regression. Results Bivariate analysis showed that none of the 11 SNPs was associated with atheroma plaque prevalence, but 3 of them (rs495392, rs562020 and rs567170) showed association with Atheromatosis progression. The multivariate analysis revealed that only rs495392 showed a statistically significant association with Atheromatosis progression, after adjustment for several parameters known to affect it in CKD patients. Thus, the presence of one allele T was associated with a reduction of 30% of the odds of progression, whereas the presence of the two T alleles was associated with a decrease close to 50%. Conclusions The presence of the allele T of the SNP rs495392 of the Klotho gene is associated with a decrease in the odds of progression of Atheromatosis in CKD patients.

  • relationship between low levels of circulating trail and Atheromatosis progression in patients with chronic kidney disease
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Angels Betriu, Elvira Fernandez, Jose M Valdivielso, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan
    Abstract:

    Background Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients. Methods Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for Atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.

  • Relationship between low levels of circulating TRAIL and Atheromatosis progression in patients with chronic kidney disease.
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Angels Betriu, Elvira Fernandez, Jose M Valdivielso, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan
    Abstract:

    Background Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients. Methods Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results The lowest levels of TRAIL at baseline were significantly (p

  • Association of the rs495392 Klotho polymorphism with Atheromatosis progression in patients with chronic kidney disease.
    Nephrology Dialysis Transplantation, 2018
    Co-Authors: Jose M Valdivielso, Elvira Fernandez, Milica Bozic, Rajesh Kumar Galimudi, Marcelino Bermúdez-lópez, Juan F. Navarro-gonzález, Angels Betriu
    Abstract:

    BACKGROUND: Prevalence of atherosclerotic cardiovascular disease and its rate of progression are higher in patients with chronic kidney disease (CKD) compared with the general population. Mineral metabolism parameters have been shown to be involved in the increased velocity of Atheromatosis progression. The aim of this study is to determine the role of 11 single-nucleotide polymorphisms (SNPs) of the Klotho gene on the rate of atherosclerosis progression in CKD. METHODS: This was a multicentre, prospective, observational study of 1439 CKD patients from the NEFRONA cohort. Carotid and femoral ultrasounds were performed at baseline and after 24 months in 10 arterial territories. Progression of Atheromatosis was defined as an increase in the number of territories with plaque. Genotyping of 11 SNPs of the Klotho gene was performed and its association with Atheromatosis progression was determined by multivariate logistic regression. RESULTS: Bivariate analysis showed that none of the 11 SNPs was associated with atheroma plaque prevalence, but 3 of them (rs495392, rs562020 and rs567170) showed association with Atheromatosis progression. The multivariate analysis revealed that only rs495392 showed a statistically significant association with Atheromatosis progression, after adjustment for several parameters known to affect it in CKD patients. Thus, the presence of one allele T was associated with a reduction of 30% of the odds of progression, whereas the presence of the two T alleles was associated with a decrease close to 50%. CONCLUSIONS: The presence of the allele T of the SNP rs495392 of the Klotho gene is associated with a decrease in the odds of progression of Atheromatosis in CKD patients.

  • factors predicting cardiovascular events in chronic kidney disease patients role of subclinical Atheromatosis extent assessed by vascular ultrasound
    PLOS ONE, 2017
    Co-Authors: Jose M Valdivielso, Angels Betriu, Montserrat Martinezalonso, David Arroyo, Marcelino Bermudezlopez, Elvira Fernandez
    Abstract:

    Patients with chronic kidney disease (CKD) have an increased incidence of cardiovascular events (CVE). The contribution of subclinical Atheromatosis extent, including femoral arteries, to CVE in CKD patients has not been investigated. In this paper, we examine the prognostic value of subclinical Atheromatosis extent, assessed as the number of arterial territories with plaque, in predicting the incidence of major and minor CVE. The NEFRONA is a multicenter, prospective cohorts study that recruited 2445 CKD subjects and 559 controls, free from previous cardiovascular disease, in 81 medical centers across Spain. The presence of atheroma plaque was assessed by arterial ultrasound in ten arterial territories (carotid and femoral). The predictive power of the presence or absence of atheroma plaque in any territory was compared with the quantification of atheroma extent as the number of territories with plaque. During the median follow up of 48 months, 216 CVE were reported. Factors predicting the incidence of CVE in the whole cohort were being male, CKD patient, lower levels of 25(OH) vitamin D, higher levels of cholesterol and the extent of subclinical Atheromatosis, yielding a higher concordance (C) index than the presence or absence of plaque. In stratified analysis including specific factors of CKD patients not on dialysis, the variables predicting CVE were the same as in the whole cohort, plus higher levels of potassium. Again, the inclusion of the information about Atheromatosis as number of territories with plaque, presented a higher C index than the presence or absence of plaque. In the dialysis population, significant variables were older age, diabetes, dialysis vintage and higher levels of cholesterol and phosphate. In this case the higher C index was obtained with the information about plaque presence. Subclinical Atheromatosis extent, including femoral arteries, influences CVE in CKD and its detection could improve the prediction of cardiovascular events.

Elvira Fernandez - One of the best experts on this subject based on the ideXlab platform.

  • association of the rs495392 klotho polymorphism with Atheromatosis progression in patients with chronic kidney disease
    Nephrology Dialysis Transplantation, 2019
    Co-Authors: Jose M Valdivielso, Elvira Fernandez, Milica Bozic, Rajesh Kumar Galimudi, Marcelino Bermudezlopez, Juan F Navarrogonzalez, Angels Betriu
    Abstract:

    Background Prevalence of atherosclerotic cardiovascular disease and its rate of progression are higher in patients with chronic kidney disease (CKD) compared with the general population. Mineral metabolism parameters have been shown to be involved in the increased velocity of Atheromatosis progression. The aim of this study is to determine the role of 11 single-nucleotide polymorphisms (SNPs) of the Klotho gene on the rate of atherosclerosis progression in CKD. Methods This was a multicentre, prospective, observational study of 1439 CKD patients from the NEFRONA cohort. Carotid and femoral ultrasounds were performed at baseline and after 24 months in 10 arterial territories. Progression of Atheromatosis was defined as an increase in the number of territories with plaque. Genotyping of 11 SNPs of the Klotho gene was performed and its association with Atheromatosis progression was determined by multivariate logistic regression. Results Bivariate analysis showed that none of the 11 SNPs was associated with atheroma plaque prevalence, but 3 of them (rs495392, rs562020 and rs567170) showed association with Atheromatosis progression. The multivariate analysis revealed that only rs495392 showed a statistically significant association with Atheromatosis progression, after adjustment for several parameters known to affect it in CKD patients. Thus, the presence of one allele T was associated with a reduction of 30% of the odds of progression, whereas the presence of the two T alleles was associated with a decrease close to 50%. Conclusions The presence of the allele T of the SNP rs495392 of the Klotho gene is associated with a decrease in the odds of progression of Atheromatosis in CKD patients.

  • relationship between low levels of circulating trail and Atheromatosis progression in patients with chronic kidney disease
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Angels Betriu, Elvira Fernandez, Jose M Valdivielso, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan
    Abstract:

    Background Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients. Methods Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for Atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.

  • Relationship between low levels of circulating TRAIL and Atheromatosis progression in patients with chronic kidney disease.
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Angels Betriu, Elvira Fernandez, Jose M Valdivielso, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan
    Abstract:

    Background Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients. Methods Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results The lowest levels of TRAIL at baseline were significantly (p

  • Association of the rs495392 Klotho polymorphism with Atheromatosis progression in patients with chronic kidney disease.
    Nephrology Dialysis Transplantation, 2018
    Co-Authors: Jose M Valdivielso, Elvira Fernandez, Milica Bozic, Rajesh Kumar Galimudi, Marcelino Bermúdez-lópez, Juan F. Navarro-gonzález, Angels Betriu
    Abstract:

    BACKGROUND: Prevalence of atherosclerotic cardiovascular disease and its rate of progression are higher in patients with chronic kidney disease (CKD) compared with the general population. Mineral metabolism parameters have been shown to be involved in the increased velocity of Atheromatosis progression. The aim of this study is to determine the role of 11 single-nucleotide polymorphisms (SNPs) of the Klotho gene on the rate of atherosclerosis progression in CKD. METHODS: This was a multicentre, prospective, observational study of 1439 CKD patients from the NEFRONA cohort. Carotid and femoral ultrasounds were performed at baseline and after 24 months in 10 arterial territories. Progression of Atheromatosis was defined as an increase in the number of territories with plaque. Genotyping of 11 SNPs of the Klotho gene was performed and its association with Atheromatosis progression was determined by multivariate logistic regression. RESULTS: Bivariate analysis showed that none of the 11 SNPs was associated with atheroma plaque prevalence, but 3 of them (rs495392, rs562020 and rs567170) showed association with Atheromatosis progression. The multivariate analysis revealed that only rs495392 showed a statistically significant association with Atheromatosis progression, after adjustment for several parameters known to affect it in CKD patients. Thus, the presence of one allele T was associated with a reduction of 30% of the odds of progression, whereas the presence of the two T alleles was associated with a decrease close to 50%. CONCLUSIONS: The presence of the allele T of the SNP rs495392 of the Klotho gene is associated with a decrease in the odds of progression of Atheromatosis in CKD patients.

  • factors predicting cardiovascular events in chronic kidney disease patients role of subclinical Atheromatosis extent assessed by vascular ultrasound
    PLOS ONE, 2017
    Co-Authors: Jose M Valdivielso, Angels Betriu, Montserrat Martinezalonso, David Arroyo, Marcelino Bermudezlopez, Elvira Fernandez
    Abstract:

    Patients with chronic kidney disease (CKD) have an increased incidence of cardiovascular events (CVE). The contribution of subclinical Atheromatosis extent, including femoral arteries, to CVE in CKD patients has not been investigated. In this paper, we examine the prognostic value of subclinical Atheromatosis extent, assessed as the number of arterial territories with plaque, in predicting the incidence of major and minor CVE. The NEFRONA is a multicenter, prospective cohorts study that recruited 2445 CKD subjects and 559 controls, free from previous cardiovascular disease, in 81 medical centers across Spain. The presence of atheroma plaque was assessed by arterial ultrasound in ten arterial territories (carotid and femoral). The predictive power of the presence or absence of atheroma plaque in any territory was compared with the quantification of atheroma extent as the number of territories with plaque. During the median follow up of 48 months, 216 CVE were reported. Factors predicting the incidence of CVE in the whole cohort were being male, CKD patient, lower levels of 25(OH) vitamin D, higher levels of cholesterol and the extent of subclinical Atheromatosis, yielding a higher concordance (C) index than the presence or absence of plaque. In stratified analysis including specific factors of CKD patients not on dialysis, the variables predicting CVE were the same as in the whole cohort, plus higher levels of potassium. Again, the inclusion of the information about Atheromatosis as number of territories with plaque, presented a higher C index than the presence or absence of plaque. In the dialysis population, significant variables were older age, diabetes, dialysis vintage and higher levels of cholesterol and phosphate. In this case the higher C index was obtained with the information about plaque presence. Subclinical Atheromatosis extent, including femoral arteries, influences CVE in CKD and its detection could improve the prediction of cardiovascular events.

Angels Betriu - One of the best experts on this subject based on the ideXlab platform.

  • are obesity indices useful for detecting subclinical Atheromatosis in a middle aged population
    Obesity Facts, 2020
    Co-Authors: Enric Sanchez, Angels Betriu, Marta Sanchez, Ferran Rius, Gerard Torres, Francesc Purroy, Reinald Pamplona, Marta Ortega, Carolina Lopezcano, Marta Hernandez
    Abstract:

    OBJECTIVE There is a close relationship between excess adiposity and cardiovascular disease. Although body mass index (BMI) is the most used approach to estimate excess weight, other anthropometric indices have been developed to measure total body and abdominal adiposity. Here, our objective was to assess the usefulness of these anthropometric indices to detect subclinical atheromatous disease. METHODS A cross-sectional study with 6,809 middle-aged subjects (mean age, 57 [53-63] years) with low to moderate cardiovascular risk from the ILERVAS project. Measures of total body fat (BMI, Clinica Universidad de Navarra - Body Adiposity Estimator [CUN-BAE], and Deurenberg's formula) and central adiposity (waist and neck circumferences, conicity index, waist-to-height ratio, Bonora's equation, the A body adiposity index, and body roundness index) were performed in all participants. Bilateral carotid and femoral ultrasound vascular studies allowed the identification of subjects with plaque. -Results: All measured indices were significantly higher in males with subclinical carotid or femoral plaques (p ≤ 0.021 for all). Also, a positive and significant correlation between all indices and the number of affected territories was found (p ≤ 0.013 for all). From the ROC analysis, all measurements identified patients with asymptomatic Atheromatosis but none of them helped make clinical decisions. Regarding females, the results were less conclusive. CONCLUSION Obesity indices are related to subclinical Atheromatosis, especially in men, in a large cohort of middle-aged subjects. However, the indices could not detect the presence of arterial plaque, so, when used in isolation, are unlikely to be decisive.

  • association of the rs495392 klotho polymorphism with Atheromatosis progression in patients with chronic kidney disease
    Nephrology Dialysis Transplantation, 2019
    Co-Authors: Jose M Valdivielso, Elvira Fernandez, Milica Bozic, Rajesh Kumar Galimudi, Marcelino Bermudezlopez, Juan F Navarrogonzalez, Angels Betriu
    Abstract:

    Background Prevalence of atherosclerotic cardiovascular disease and its rate of progression are higher in patients with chronic kidney disease (CKD) compared with the general population. Mineral metabolism parameters have been shown to be involved in the increased velocity of Atheromatosis progression. The aim of this study is to determine the role of 11 single-nucleotide polymorphisms (SNPs) of the Klotho gene on the rate of atherosclerosis progression in CKD. Methods This was a multicentre, prospective, observational study of 1439 CKD patients from the NEFRONA cohort. Carotid and femoral ultrasounds were performed at baseline and after 24 months in 10 arterial territories. Progression of Atheromatosis was defined as an increase in the number of territories with plaque. Genotyping of 11 SNPs of the Klotho gene was performed and its association with Atheromatosis progression was determined by multivariate logistic regression. Results Bivariate analysis showed that none of the 11 SNPs was associated with atheroma plaque prevalence, but 3 of them (rs495392, rs562020 and rs567170) showed association with Atheromatosis progression. The multivariate analysis revealed that only rs495392 showed a statistically significant association with Atheromatosis progression, after adjustment for several parameters known to affect it in CKD patients. Thus, the presence of one allele T was associated with a reduction of 30% of the odds of progression, whereas the presence of the two T alleles was associated with a decrease close to 50%. Conclusions The presence of the allele T of the SNP rs495392 of the Klotho gene is associated with a decrease in the odds of progression of Atheromatosis in CKD patients.

  • relationship between low levels of circulating trail and Atheromatosis progression in patients with chronic kidney disease
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Angels Betriu, Elvira Fernandez, Jose M Valdivielso, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan
    Abstract:

    Background Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients. Methods Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for Atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.

  • Relationship between low levels of circulating TRAIL and Atheromatosis progression in patients with chronic kidney disease.
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Angels Betriu, Elvira Fernandez, Jose M Valdivielso, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan
    Abstract:

    Background Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients. Methods Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results The lowest levels of TRAIL at baseline were significantly (p

  • Association of the rs495392 Klotho polymorphism with Atheromatosis progression in patients with chronic kidney disease.
    Nephrology Dialysis Transplantation, 2018
    Co-Authors: Jose M Valdivielso, Elvira Fernandez, Milica Bozic, Rajesh Kumar Galimudi, Marcelino Bermúdez-lópez, Juan F. Navarro-gonzález, Angels Betriu
    Abstract:

    BACKGROUND: Prevalence of atherosclerotic cardiovascular disease and its rate of progression are higher in patients with chronic kidney disease (CKD) compared with the general population. Mineral metabolism parameters have been shown to be involved in the increased velocity of Atheromatosis progression. The aim of this study is to determine the role of 11 single-nucleotide polymorphisms (SNPs) of the Klotho gene on the rate of atherosclerosis progression in CKD. METHODS: This was a multicentre, prospective, observational study of 1439 CKD patients from the NEFRONA cohort. Carotid and femoral ultrasounds were performed at baseline and after 24 months in 10 arterial territories. Progression of Atheromatosis was defined as an increase in the number of territories with plaque. Genotyping of 11 SNPs of the Klotho gene was performed and its association with Atheromatosis progression was determined by multivariate logistic regression. RESULTS: Bivariate analysis showed that none of the 11 SNPs was associated with atheroma plaque prevalence, but 3 of them (rs495392, rs562020 and rs567170) showed association with Atheromatosis progression. The multivariate analysis revealed that only rs495392 showed a statistically significant association with Atheromatosis progression, after adjustment for several parameters known to affect it in CKD patients. Thus, the presence of one allele T was associated with a reduction of 30% of the odds of progression, whereas the presence of the two T alleles was associated with a decrease close to 50%. CONCLUSIONS: The presence of the allele T of the SNP rs495392 of the Klotho gene is associated with a decrease in the odds of progression of Atheromatosis in CKD patients.

Petros P Sfikakis - One of the best experts on this subject based on the ideXlab platform.

  • accelerated Atheromatosis and arteriosclerosis in primary systemic vasculitides current evidence and future perspectives
    Current Opinion in Rheumatology, 2018
    Co-Authors: Ourania D Argyropoulou, Athanase D Protogerou, Petros P Sfikakis
    Abstract:

    Purpose of reviewPrimary systemic vasculitides (PSV) encompass a subset of autoimmune diseases, characterized by inflammation of blood vessels. Atheromatosis and arteriosclerosis may be accelerated in several PSV and account for the increased rate of cardiovascular morbidity that some exhibit. We ai

  • rheumatoid arthritis is sufficient to cause Atheromatosis but not arterial stiffness or hypertrophy in the absence of classical cardiovascular risk factors
    Clinical Rheumatology, 2015
    Co-Authors: Aikaterini Arida, Evi Zampeli, George Konstantonis, Kalliope Fragiadaki, George D Kitas, Athanasios Protogerou, Petros P Sfikakis
    Abstract:

    Rheumatoid arthritis (RA) associates with increased cardiovascular disease (CVD) mortality thought to be due to accelerated arterial disease. Different components of arterial disease, namely, Atheromatosis, arteriosclerosis, and arterial wall hypertrophy, are differentially affected by classical CVD risk factors, which are highly prevalent in these patients. We hypothesized that RA disease per se may also differentially affect these components. Of 267 consecutive RA patients, we selected specifically those who were free of established CVD and CVD risk factors (18 %); of them, 41 patients (36 women, 49 ± 13 years) could be matched effectively 1:1 for age and gender to healthy controls. Atheromatosis was assessed by the presence of carotid and/or femoral artery plaques, arteriosclerosis by pulse wave velocity and local wall elasticity, and arterial hypertrophy by intima-media thickness and cross-sectional area. More patients had atheromatic plaques than controls (29 vs. 12 %, p = 0.039), and multiarterial Atheromatosis was more prevalent in RA (22 vs. 2 %, p = 0.026). Accelerated Atheromatosis was not associated with rheumatoid factor, or anti-cyclic citrullinated peptide (CCP) autoantibody status. Plaque burden in patients with less than 5 years disease duration (aged 41 ± 13 years) was comparable to their matched controls. In contrast, all indices of arterial stiffness and hypertrophy were similar between controls and RA patients, even in those with long-standing disease. RA per se is sufficient to cause Atheromatosis in the absence of classical CVD risk factors, but has minimal, if any, effect on arteriosclerosis and arterial wall hypertrophy.

  • sat0109 accelerated subclinical Atheromatosis but not arterial stiffness or hypertrophy in rheumatoid arthritis patients free of classical risk factors
    Annals of the Rheumatic Diseases, 2014
    Co-Authors: Aikaterini Arida, Evi Zampeli, George Konstantonis, George D Kitas, Athanasios Protogerou, K Fragkiadaki, Petros P Sfikakis
    Abstract:

    Background Several lines of evidence indicate that classical cardiovascular disease (CVD) risk factors, such as arterial hypertension, diabetes mellitus, smoking and dyslipidemia, are significantly increased in rheumatoid arthritis (RA), which, in turn, is associated with 1.5- to 2-fold increased prevalence of CVD. The exact contribution of the RA disease per se in this association, in terms of systemic inflammation, drugs, disease-related genetics and/or other factors, remains under study. Objectives We aimed to test the hypothesis that RA per se in patients free of classical CVD risk factors is associated with accelerated subclinical arterial disease. Methods Consecutive patients with RA (n=267) were comprehensively studied by ultrasound for, a) subclinical Atheromatosis assessed by the presence of carotid artery and/or femoral artery plaques, b) stiffness of common carotid artery and aortic stiffness by pulse wave velocity, and, c) hypertrophy of common carotid artery assessed by intimal-medial thickness and cross sectional area (calculated adjacent to plaques, when plaques were present). Of all patients, we identified those who were CVD-free, non-smokers, without hypertension, diabetes and dyslipidemia (only 18%). Of them, 41 (aged 49±13 years, 36 women, median disease duration of 7 years, range 3-19 years) were compared to 41 healthy non-smokers, without hypertension, diabetes and dyslipidemia who were effectively matched 1:1 for age and gender and studied in parallel. Results Patients had more than 2-fold higher prevalence of carotid and/or femoral atheromatic plaques than healthy controls (29% vs. 12%, p=0.05). All patients with plaques had an acceptable functional status of class I or II. Moreover, body mass index, as well as family history of CVD, was similar between patients with plaques and their matched controls. Multi-arterial subclinical Atheromatosis, defined as plaque presence at more than 1 of 8 arterial sites evaluated, was by far more prevalent in RA patients than controls (22% vs. 2%, p=0.007). Notably, plaque burden in the subgroup of RA patients with less than 5 years of disease duration was comparable to their matched controls. Either arterial stiffness or hypertrophy, however, was not significantly increased compared to controls, even in patients with long-standing RA. Conclusions These data directly show for the first time an acceleration of Atheromatosis in RA, but not of arterial stiffness or hypertrophy, independently of the classical CVD risk factors. This phenomenon is not evidenced during the first 5 years after disease onset and seems to be chronic inflammation-dependent. Also, the dissociation between Atheromatosis and arterial stiffness in this selected population suggests a minimal, if any, effect of chronic inflammation in arterial remodeling. Studies testing whether early and effective RA clinical disease control prevents the development of arterial damage in the long-term are ongoing. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5811

  • subclinical femoral Atheromatosis in rheumatoid arthritis comparable prevalence to diabetes mellitus in a case control study
    Annals of the Rheumatic Diseases, 2012
    Co-Authors: Athanase D Protogerou, George D Kitas, Evangelia Zampeli, Nikos Tentolouris, Kostas Makrilakis, Petros P Sfikakis
    Abstract:

    Objective Rheumatoid arthritis (RA) is associated with increased coronary artery disease (CAD) and subclinical carotid Atheromatosis, reportedly to equal diabetes mellitus (DM). The presence of atheromatic plaques in femoral arteries of RA patients without DM was compared with with DM patients. Methods Femoral plaques were recorded in 30 (17 men, age 43.0±12 years, disease duration 9.9±7.1 years) and 60 older RA patients (27 men, age 63.0±7.1 years, disease duration 11.4±7.9 years) matched 1:1 for age, gender and disease duration with DM types 1 and 2 patients, respectively. All were asymptomatic and free of CAD. Results The number of femoral plaques per patient in either RA subgroup was comparable with DM (0.64±0.82 vs 0.77±0.89 in total respective populations, p=0.340); percentages of patients with femoral plaques were also comparable (RA vs DM type 1 20% and 13%, respectively; RA vs DM type 2 58% and 66%, respectively). Hypertension and dyslipidaemia were significantly more frequent in both DM groups than RA groups. Conclusions Subclinical femoral Atheromatosis in RA is analogous to DM, further confirming the territorial unrestricted acceleration of the atheromatic process in these patients. Cardiovascular risk stratification based on both carotid and femoral plaque detection in RA should be addressed prospectively.

Abdolhamid Sheikhzadeh - One of the best experts on this subject based on the ideXlab platform.

  • predictive value of inflammatory and hemostatic parameters atherosclerotic risk factors and chest x ray for aortic arch Atheromatosis
    Stroke, 2003
    Co-Authors: Philipp Ehlermann, Wladimir Mirau, Jurgen Jahn, Andrew Remppis, Abdolhamid Sheikhzadeh
    Abstract:

    Background and Purpose— Aortic arch Atheromatosis (AAA) is a common cause of cerebral embolism. Transesophageal echocardiography (TEE) shows not only the extension of atherosclerotic plaques but also the mobility of superimposed thrombi. In most cases AAA is only detected after the embolic event. This study was therefore designed to identify predictive factors for AAA. Methods— One hundred seven consecutive patients referred for routine TEE were included in the study. Patients on warfarin therapy, with a history of recent surgery, or with any signs of infectious, immunological, or malignant diseases were excluded. Results— Diabetes mellitus carried the highest risk for AAA (odds ratio, 3.0), followed by hyperlipidemia (2.5) and arterial hypertension (2.3). Age >70 years was accompanied with a 1.8-fold increased risk. Patients with aortic calcifications on standard chest x-ray had a 4.6-fold higher prevalence. Severe AAA was associated with higher levels of C-reactive protein (14.6±14.1 versus 4.9±7.2 mg/L...

  • systemic embolism in aortic arch Atheromatosis
    European Heart Journal, 1994
    Co-Authors: R Mitusch, U Stierle, C Tepe, D Kummerkloess, Ch Kessler, Abdolhamid Sheikhzadeh
    Abstract:

    : The role of aortic Atheromatosis as a risk factor for systemic embolism and its relationship to other potential sources of embolism was examined in 335 patients undergoing transoesophageal echocardiography for various clinical reasons. Multiple logistic regression analysis revealed a significant correlation between embolism and moderate (atheroma protruding less than 5 mm into the aortic lumen, grade 2) to complex (atheroma protruding at least 5 mm into the vessel lumen with or without mobile components, grade 3) atherosclerosis of the aortic arch. Odds ratios were 4.0 for grade 2 Atheromatosis (95% CI 1.1-14.4; P < 0.05) and 9.7 for grade 3 Atheromatosis (95% CI 1.5-61.0; P < 0.05). Other significant associations were found with cardiac thrombi (odds ratio 4.0, 95% CI 1.7-9.3; P < 0.005) and hypertension (odds ratio 1.8, 95% CI 1.0-3.3; P < 0.05). In a subset of 163 patients in whom results of an ultrasound examination were available, atherosclerosis of the carotid arteries was another significant marker of embolism (odds ratio 2.0, 95% CI 1.2-3.3; P < 0.01). In conclusion, aortic arch Atheromatosis, which was predominantly recognized in patients with cerebrovascular events of undetermined cause, seems to carry a risk of embolism that is comparable to cardiac and carotid atherosclerosis.